Complement‐targeted therapeutics: Are we there yet, or just getting started?. Daniel Ricklin
After a hesitant start, the number of available therapeutics that target the human complement system has surged from one to a dozen drugs in less than 20 years. Meanwhile, the clinical arsenal encompasses treatment modalities directed to several targets for the therapy of a steadily growing spectrum of complement-related disorders. Abstract Therapeutic interventions in the … Read more